Answers are grounded in this paper and cite their sources.
We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.
No takes yet. Share an insight, caveat, or question.
Rooney et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: